Your activity: 22 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Pharmacokinetic profile of common hallucinogens

Pharmacokinetic profile of common hallucinogens
Drug/substance Typical dose Kinetics following ingestion (see NOTE)
Onset (minutes) Peak effect (hours) Duration of effects (hours)
25B-NBMOe 

Oral (buccal) or nasal: 250-500 micrograms

 20-40 0.5-4 12-16
25C-NBOMe 

Oral (buccal) or nasal: 200-1000 micrograms

 1-15 0.5-4 4-10
25I-NBOMe Oral (buccal) or nasal: 500-800 micrograms  1-17  0.5-2  6-10 
AMT (α-methyltryptamine)

Oral: 20-40 mg

Smoked: 6-10 mg		 20-30 4-8 12-16
DMT (dimethyltryptamine; N,N-dimethyltryptamine)

Oral: 35-75 mg

IV, smoked: 30-150 mg		 20-60 1-2 2-8
Dextromethorphan Oral: 100-600 mg 15-30 2.5 4-6*
5-MeO-DIPT (Foxy methoxy)

Oral: 5-30 mg

Nasal: 5-20 mg

Smoked: 2-15 mg		 20-60 1-2 3-6
Hawaiian baby woodrose (Argyreia nervosa) Oral: 5-10 seeds ND ND 6-8
Ibogaine Oral: 10 mg/kg 45-120 4-8 18-24
Ketamine

Oral: 200-300 mg

IV: 50-100 mg

IM: 75-125 mg

Nasal: 60-250 mg		 15-20 0.5-1 1.5-2
LSD (lysergic acid diethylamide) Oral: 25-200 micrograms 30-90 3-5 6-12
Mescaline (peyote) Oral: 200-500 mg (6-12 dried buttons) 30-120 2-4 6-12
Morning glory (Ipomoea violacae) Oral: 200-300 seeds 60 ND 6-10
PCP (phencyclidine)

Oral: 2-6 mg

IV, nasal, smoked: 1-3 mg		 30-60 1-4 4-6
Psilocybin Oral: 10 mg (20-30 g fresh mushrooms; 1-2 g dried mushroom powder) 20-30 1-2 6-8
Salvia divinorum

Oral: 1 mg (5-10 leaves)

Smoked: 200-500 micrograms		 3-15 1 1-3
NOTE: Kinetics shown are for oral doses. For most substances, peak levels following injection, nasal insufflation, or smoking occur within 1 to 5 minutes.
ND: no data available for this parameter.
* For rapid metabolizers (majority), who have high CYP2D6 activity; for poor metabolizers, duration of action can exceed 24 hours.
Data for table adapted from:
  1. Drug Enforcement Administration, US Department of Justice. Drugs and Chemicals of Concern. http://www.deadiversion.usdoj.gov/drug_chem_info/index.html. (Accessed July 23, 2012).
  2. Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101:131.
  3. The Vaults of Erowid. http://www.erowid.org/psychoactives. (Accessed July 23, 2012).
  4. Baselt RC. Disposition of Toxic Drugs in Man, 9th ed. Biomedical Publications, Foster City, 2011.
Graphic 50447 Version 5.0